PPM1DMosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations

The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population

(2014) H. Song et al.   HUMAN MOLECULAR GENETICS

RE: PPM1D Mutations in Circulating White Blood Cells and the Risk for Ovarian Cancer

(2014) H. Qiu   JNCI-Journal of the National Cancer Institute

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma — Analysis of patient data in the prospective OVCAD study

(2013) G. Hofstetter et al.   GYNECOLOGIC ONCOLOGY

Molecular Wanderings Through the DNA Damage Response and Risk for Ovarian Cancer

(2013) M. A. Bookman   JNCI-Journal of the National Cancer Institute

PPM1D Mutations in Circulating White Blood Cells and the Risk for Ovarian Cancer

(2013) Mohammad R. Akbari et al.   JNCI-Journal of the National Cancer Institute

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer

(2013) Paul D P Pharoah et al.   NATURE GENETICS

Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials

(2012) S. Mahner et al.   EUROPEAN JOURNAL OF CANCER

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer

(2012) Elise Ruark et al.   NATURE

Fast and accurate long-read alignment with Burrows–Wheeler transform

(2010) Heng Li et al.   BIOINFORMATICS

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

(2010) A. McKenna et al.   GENOME RESEARCH